AXSOME THERAPEUTICS, INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- AXSOME THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $9.98M, a 41.41% decline year-over-year.
- AXSOME THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $15.52M, a 23.49% decline year-over-year.
- AXSOME THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $11.66M.
- AXSOME THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-03-31 was $17.04M, a 581.13% increase year-over-year.
- AXSOME THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2023 was $12.42M, a 98.67% increase from fiscal 2022.
- AXSOME THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2022 was $6.25M, a 42.00% increase from fiscal 2021.
- AXSOME THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2021 was $4.40M, a 319.30% increase from fiscal 2020.
- AXSOME THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2020 was $1.05M, a 8.22% decline from fiscal 2019.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-03-31 | $9.98M 10-Q · filed 2026-08-10 | |
| 2025-09-30 | $15.52M 10-Q · filed 2025-11-03 | |
| 2025-06-30 | $11.66M 10-Q · filed 2025-08-04 | |
| 2025-03-31 | $17.04M 10-Q · filed 2026-08-10 | |
| 2024-09-30 | $20.29M 10-Q · filed 2025-11-03 | |
| 2024-03-31 | $2.50M 10-Q · filed 2025-11-03 | |
| 2023-12-31 | $12.42M 10-K · filed 2026-02-23 | |
| 2023-09-30 | $4.32M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $6.57M 10-Q · filed 2024-11-12 | |
| 2023-03-31 | $387.00K 10-Q · filed 2024-11-12 | |
| 2022-12-31 | $6.25M 10-K · filed 2025-02-18 | |
| 2022-09-30 | $3.06M 10-Q · filed 2023-11-06 | |
| 2022-06-30 | $176.00K 10-Q · filed 2023-11-06 | |
| 2022-03-31 | $182.00K 10-Q · filed 2023-11-06 | |
| 2021-12-31 | $4.40M 10-K · filed 2024-02-23 | |
| 2021-09-30 | $438.68K 10-Q · filed 2022-11-07 | |
| 2021-06-30 | $958.89K 10-Q · filed 2022-11-07 | |
| 2021-03-31 | $1.91M 10-Q · filed 2022-11-07 | |
| 2020-12-31 | $1.05M 10-K · filed 2023-02-28 | |
| 2020-09-30 | $190.23K 10-Q · filed 2021-11-08 | |
| 2020-06-30 | $190.41K 10-Q · filed 2021-11-08 | |
| 2020-03-31 | $629.76K 10-Q · filed 2021-11-08 | |
| 2019-12-31 | $1.14M 10-K · filed 2022-03-01 | |
| 2019-09-30 | $483.84K 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $205.34K 10-Q · filed 2020-11-05 | |
| 2019-03-31 | $410.16K 10-Q · filed 2020-11-05 | |
| 2018-12-31 | $380.32K 10-K · filed 2021-03-01 | |
| 2017-12-31 | $316.72K 10-K · filed 2020-03-12 | |
| 2016-12-31 | $33.03K 10-K · filed 2017-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |